Connect with us

Business

Top CBD companies experience market share drop as online sales soften

Published

on

The largest CBD companies in the U.S. experienced declining market share in the second quarter, as the return of in-person shopping triggered a decline in e-commerce sales.

Market share by revenue for the top 20 CBD brands shrank 2 percentage points, to 16%, versus the first quarter of the year, according to Chicago-based cannabis analytics firm Brightfield Group.

That is the smallest share for the sector in the past four quarters. The brands’ share of overall CBD sales peaked in the fourth quarter of 2021, at 18.9%.

Bethany Gomez, Brightfield’s managing director, said the declining market share reflects a broader trend in the direct-to-consumer category, with consumers returning to stores after having shopped online following the outbreak of the COVID-19 pandemic in early 2020

“There’s still a very strong percentage of consumers that are buying online, but people are ready to explore a little bit more,” Gomez said.

“They’re going out to stores. They’re going out to farmers markets. They’re going out to all these kinds of independent retailers that are starting to now pick up a larger percentage of share.”

That shift has allowed smaller CBD companies to increase their share of overall sales to 71% in the second quarter, up from 67% in the first.

In addition, independent pharmacies that previously were a strong revenue source for CBD brands also have returned, having earlier focused their attention on COVID-19 testing and vaccinations.

That one-two combination is spurring large CBD companies to possibly pivot back to brick-and-mortar sales after having shifted large parts of their operations to online sales as pandemic lockdowns stalled in-person shopping.

Charlotte’s Web, which Brightfield ranks No. 1 among CBD brands, reported that its direct-to-consumer online sales decreased 15.3%, or $2.4 million, to $13.3 million in the second quarter from a year earlier as fewer people visited the Colorado company’s e-commerce website.

That said, Charlotte’s Web still leads online CBD sales with 2.7% of the market in the second quarter. It also ranked third in brick-and-mortar sales, according to Brightfield, with 1.9% of that sector.

When it comes to CBD, online selling remains the dominant distribution channel, accounting for 39.2% of overall sales.

Pharmacies follow with a 19.5% share while CBD specialty retailers make up 10.7%.

Overall, the CBD market rankings are stable at the top.

Movement by revenue remained largely unchanged among the top 20 brands compared to the first quarter, except for the addition of Flora Growth.

The cannabis cultivator and product manufacturer now ranks sixth following its acquisition of JustCBD brand in early 2022 for $16 million plus privately issued shares.

Gomez believes the continued strength of sales at independent retail outlets will stave off any consolidation the industry might have expected.

“There’s just not any big forces pushing that aspect forward, so we’re just continuing to see all of these tiny little players operate in small areas of the country through small independent channels now, with few of them really being able to scale up further,” she said.

Sales of the prescription drug Epidiolex, a highly purified CBD oil used to treat rare forms of epilepsy, continues to claim a significant portion of the U.S. CBD market.

Tracked separately from consumer CBD by Brightfield, the drug accounted for 13% of the total U.S. CBD market by revenue, a decline from a 15% share in the first quarter.

But overall sales are up.

Also available in the United Kingdom, Germany, Italy, Spain, and soon France, global net sales of Epidiolex – known as Epidyolex outside the U.S. – increased 12%, to $175.3 million, in the second quarter on a proforma basis versus the same period in 2021.

Jazz Pharmaceuticals, which acquired the cannabis drug maker GW Pharmaceutical last year, said the increase in sales was due to higher sales volume and price increases in 2021 and 2022.

Source: https://mjbizdaily.com/top-cbd-companies-experience-market-share-drop-as-online-sales-soften/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News